Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Total Valuation
Lyra Therapeutics has a market cap or net worth of $6.21M. The enterprise value is $20.86M.
Market Cap$6.21M
Enterprise Value$20.86M
Share Statistics
Lyra Therapeutics has 1,774,882 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,774,882
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Lyra Therapeutics’s return on equity (ROE) is -8.06 and return on invested capital (ROIC) is -166.66%.
Return on Equity (ROE)-8.06
Return on Assets (ROA)-1.41
Return on Invested Capital (ROIC)-166.66%
Return on Capital Employed (ROCE)-1.79
Revenue Per Employee51.13K
Profits Per Employee-3.11M
Employee Count30
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyra Therapeutics is ―. Lyra Therapeutics’s PEG ratio is -0.53.
PE Ratio―
PS Ratio438.05
PB Ratio57.96
Price to Fair Value57.96
Price to FCF-9.29
Price to Operating Cash Flow-0.12
PEG Ratio-0.53
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 1.53M and earned -93.44M in profits. Earnings per share was -1.43.
Revenue1.53M
Gross Profit1.53M
Operating Income-96.35M
Pretax Income-93.40M
Net Income-93.44M
EBITDA-60.26M
Earnings Per Share (EPS)-1.43
Cash Flow
In the last 12 months, operating cash flow was -34.15M and capital expenditures 38.00K, giving a free cash flow of -34.11M billion.
Operating Cash Flow-34.15M
Free Cash Flow-34.11M
Free Cash Flow per Share-19.22
Dividends & Yields
Lyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.57
52-Week Price Change-66.22%
50-Day Moving Average5.79
200-Day Moving Average7.58
Relative Strength Index (RSI)32.86
Average Volume (3m)66.06K
Important Dates
Lyra Therapeutics upcoming earnings date is Mar 11, 2026, After Close (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 11, 2026
Ex-Dividend Date―
Financial Position
Lyra Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 2002.34%
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap0.00
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyra Therapeutics has paid 39.00K in taxes.
Income Tax39.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Lyra Therapeutics EV to EBITDA ratio is -11.05, with an EV/FCF ratio of -9.20.
EV to Sales434.01
EV to EBITDA-11.05
EV to Free Cash Flow-9.20
EV to Operating Cash Flow-9.51
Balance Sheet
Lyra Therapeutics has ― in cash and marketable securities with $31.38M in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt$31.38M
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share$0.18
Margins
Gross margin is 74.03%, with operating margin of -6280.83%, and net profit margin of -6090.94%.
Gross Margin74.03%
Operating Margin-6280.83%
Pretax Margin-6088.40%
Net Profit Margin-6090.94%
EBITDA Margin-3928.42%
EBIT Margin-3959.13%
Analyst Forecast
The average price target for Lyra Therapeutics is $16.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$16.00
Price Target Upside357.14% Upside
Analyst ConsensusHold
Analyst Count3
Revenue Growth Forecast-59.21%
EPS Growth Forecast68.97%